MINT1526A

· Genentech, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MINT1526A, covering 2016-11-02 to 2016-11-02. Get the full timeline:

Most recent: Clinical Trial Update: A Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors [Phase 1]

See pricing